Background
Medulloblastoma (MB), a tumor of the cerebellum, is the most common malignant brain tumor in children. Despite aggressive treatment with surgical resection, radiation and chemotherapy, only 60% of children are cured of the tumor and most suffer life-long, devastating side effects including reduced intellect. The main problem with current treatments for MB is that they are not very specific for MB tumor cells. Thus, there is a critical need to develop new cancer therapies that selectively kill MB tumor cells.
